Darcalma (Hyoscyamine Sulfate / Methenamine / Phenyl Salicylate / Sodium Phosphate, Monobasic / Methylene Blue) - Summary

DARCALMA SUMMARY

Hyoscyamine Sulfate is a parasympatholytic which relaxes smooth muscles and thus produces an antispasmodic effect. Methenamine, after oral administration, undergoes hydrolysis and generates formaldehyde, which provides bactericidal or bacteriostatic action. a mild analgesic for pain relief. Sodium Phosphate, Monobasic increases urinary acidity helping to maintain an acid pH necessary for the degradation of methenamine. Methylene Blue is a monoamine oxidase inhibitor with weak antiseptic properties.

Darcalma is indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures.

See all Darcalma indications & dosage >>

NEWS HIGHLIGHTS

Clinical Trials Related to Darcalma (Hyoscyamine / Methenamine / Phenyl Salicylate / Sodium Cation / Methylene Blue)

Use of Tamsulosin to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery [Recruiting]
Postoperative urinary retention is a frequent complication of spinal surgeries and impacts a large portion of this population which results in increased morbidity as a result of increased number of catheterizations, urinary tract infections (UTIs) and prolonged hospital stays. With the addition of Tamsulosin, the investigators would anticipate a reduction in the incidence and duration of postoperative urinary retention and therefore a reduction in morbidity related to treatment of urinary retention as well as shortened hospital stays.

more trials >>